Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890859 | 0.91 | MAPK14 (0.64) | MAPK14PTGS2 | |
| SCHEMBL3886784 | 0.91 | MAPK14 (0.69) | MAPK14PTGS2 | |
| SCHEMBL3886817 | 0.90 | MAPK14 (0.81) | MAPK14PTGS2PIK3C3 | |
| SCHEMBL3891723 | 0.86 | MAPK14 (0.54) | MAPK14KDM4E | |
| SCHEMBL3890142 | 0.82 | MAPK14 (0.63) | MAPK14 | |
| SCHEMBL3887400 | 0.81 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL3888138 | 0.81 | MAPK14 (0.83) | MAPK14 | |
| SCHEMBL4266052 | 0.80 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL3886770 | 0.79 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL6842823 | 0.79 | MAPK14 (0.49) | MAPK14PIK3C3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | claimed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | claimed |
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7199124-B2 | JNK inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885PTGS2 57/4885PIK3C3 379/4885 |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | MAPK1, MAP4K2, MAPK4 | MAPK14 31/4885PTGS2 766/4885PIK3C3 352/4885 |
| US-20040063946-A1 | Jnk inhibitor | MAPK1, MAPK7, MAP3K7 | MAPK14 14/4885PTGS2 2590/4885PIK3C3 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.